deltatrials
Completed PHASE3 NCT00479388

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.

Sponsor: Merck Sharp & Dohme LLC

Conditions Mixed Dyslipidemia Primary Hypercholesterolemia
Interventions Comparator: atorvastatin calcium Comparator: simvastatin niacin (+) laropiprant
Updated 7 times since 2017 Last updated: Feb 20, 2015 Started: Jul 31, 2007 Primary completion: Jul 31, 2008 Completion: Oct 31, 2008

This PHASE3 trial investigates Mixed Dyslipidemia and Primary Hypercholesterolemia and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.